Abstract：Objective To explore the feasibility and safety of dimethyldiguanide as an adjuvant therapy in the treatment of nonalcoholic fatty liver disease.Methods From March 2012 to September 2014，180 patients with nonalcoholic fatty liver diseases admitted into our hospital were selected and evenly divided into observation group and control group one and control group two in random.In the control group one，polyene phosphatidyl choline was used，in the control group two，dimethyldiguanide was adopted，and in the observation group，these two drugs in combination were applied.The liver function，blood lipids，insulin resistance and degree of hepatic steatosis were compared among three groups.Results In the control group one，homeostasis model assessment of insulin resistance（HOMA-IR）and triglyceride（TG）in the control group two were compared with no statistical difference（P＞0.05）.The levels of aspartate aminotransferase（AST）and total cholesterol（TC）were not in statistical significance after therapy in inter-group comparison （P＞0.05）.Level of alanine aminotransferase（ALT），AST，TC，and degree of hepatic steatosis were greatly decreased compared with prior treatment（P＜0.05）.The total effective rates in the control group one and two，and observation group were 86.67%，85.00%，and 91.67% respectively with statistical difference（P＜0.05）.Conclusion Dimethyldiguanide as an adjuvant therapy in the treatment of nonalcoholic fatty liver disease can obtain a definite effect in high safety，which is worthy of clinical promotion.
刘真； 罗利华； 黄必武. 二甲双胍辅助治疗非酒精性脂肪肝的可行性及安全性[J]. 中国当代医药, 2016, 23(17): 129-131转135.
LIU Zhen； LUO Li-hua； HUANG Bi-wu. Feasibility and safety of dimethyldiguanide as an adjuvant therapy in the treatment of nonalcoholic fatty liver disease. 中国当代医药, 2016, 23(17): 129-131转135.
京公网安备 11010502046607号